Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Immunocore Holdings (IMCR) over the last 3 years, with Dec 2024 value amounting to $185.5 million.

  • Immunocore Holdings' Accumulated Expenses fell 26.51% to $144.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.9 million, marking a year-over-year decrease of 26.51%. This contributed to the annual value of $185.5 million for FY2024, which is 54.82% up from last year.
  • Per Immunocore Holdings' latest filing, its Accumulated Expenses stood at $185.5 million for FY2024, which was up 54.82% from $119.8 million recorded in FY2023.
  • Immunocore Holdings' Accumulated Expenses' 5-year high stood at $185.5 million during FY2024, with a 5-year trough of $76.7 million in FY2022.
  • In the last 3 years, Immunocore Holdings' Accumulated Expenses had a median value of $119.8 million in 2023 and averaged $127.4 million.
  • Data for Immunocore Holdings' Accumulated Expenses shows a peak YoY soared of 56.14% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Immunocore Holdings' Accumulated Expenses stood at $76.7 million in 2022, then soared by 56.14% to $119.8 million in 2023, then surged by 54.82% to $185.5 million in 2024.